How IMM-101 works
IMM-101 is an investigational medicinal product. It is intended to be used in combination with other standard-of-care anti-cancer treatments, such as immune checkpoint inhibitors and chemotherapy, to improve the overall outcome for patients without substantially compromising on patient’s safety and quality of life. Early phase clinical studies have produced encouraging safety results and increases in survival in patients with metastatic pancreatic cancer and advanced (unresectable) melanoma.
IMM-101 contains a naturally occurring, heat-killed whole cell Mycobacterium called M. obuense. This bacterium is part of the Immodulon family of immunomodulators derived from carefully selected bacteria belonging to the Actinomycetales order of bacteria, which in their wider application can potentially be used as immunotherapy treatments in cancer or in certain diseases associated with chronic inflammation and as a vaccine for tuberculosis.
IMM-101 Mechanism of Action (MoA)
IMM-101’s main MoA is that it activates early stage dendritic cells and skews their maturation into dendritic cells that induce Type I immune responses ultimately resulting in the generation of cytotoxic T cells, which are essential for killing cancer cells. In addition, IMM-101 treatment results in the activation and multiplication of various other immune cells involved in controlling cancer.